|
|
Active Org.- |
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanismadrenergic receptor agonists [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
100 Clinical Results associated with Cognition Pharmaceuticals, LLC
0 Patents (Medical) associated with Cognition Pharmaceuticals, LLC
100 Deals associated with Cognition Pharmaceuticals, LLC
100 Translational Medicine associated with Cognition Pharmaceuticals, LLC